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ABSTRACT
There is growing interest in the use of plant bioresources for managing  Type 2 diabetes. In this study, Rhodamnia cinerea, 
which is used traditionally to manage diseases in Malaysia, was explored for its antidiabetic effects. Type 2 diabetic rats 
were managed for 4 weeks using aqueous extract of R. cinerea or quercetin. Weights and fasting glucose were measured 
weekly, while serum lipid profiles, insulin, antioxidant status, urea, creatinine and liver enzymes were assayed at the 
end. Sorbitol contents, antioxidant capacities and aldose reductase activities of the kidney, lens and sciatic nerve were 
also assessed. The results showed that the aqueous extract of R. Cinerea mainly contained Myricitrin and it reduced 
glycemia (p>0.05), lipid profiles (p<0.05), F2-isoprostanes (p<0.05) and overall metabolic condition of type 2 diabetic 
rats. R. cinerea also attenuated sorbitol contents of the nerve (p<0.05) and kidney (p<0.05), partly through regulating 
the activity of aldose reductase (p<0.05 for nerve) and sorbitol dehydrogenase (p<0.05 for kidney) in comparison with 
diabetic untreated group. Quercetin is a known aldose reductase inhibitor and can improve several metabolic indices 
related to Type 2 diabetes. In this study, the results of R. cinerea were comparable to or better than those of quercetin, 
suggesting that R. cinerea extract can be a good candidate for managing Type 2 diabetes and its complications related 
to sorbitol accumulation. 
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ABSTRAK
Terdapat minat yang meningkat dalam penggunaan sumber biologi tumbuhan untuk menguruskan Diabetes Jenis 2. 
Dalam kajian ini, Rhodamnia cinerea yang digunakan secara tradisi untuk menguruskan penyakit di Malaysia, telah 
dikaji untuk kesan antidiabetik. Tikus diabetik Jenis 2 dikendalikan selama 4 minggu menggunakan ekstrak akues R. 
cinerea atau quercetin. Berat dan paras glukosa puasa diukur setiap minggu, manakala profil serum lipid, insulin, 
status antioksidan, urea, kreatinin dan enzim hati telah dicerakin pada peringkat akhir. Kandungan sorbitol, kapasiti 
antioksidan dan aktiviti aldosa reduktase buah pinggang, kanta dan saraf sciatik turut dinilai. Hasil kajian menunjukkan 
bahawa ekstrak akues R. cinerea mengandungi Myricitrin dan memperbaiki glisemia (p>0.05), profil lipid (p<0.05), 
F2-isoprostanes (p<0.05) dan keadaan keseluruhan metabolik tikus Diabetes Jenis 2 R. cinerea juga mengurangkan 
kandungan sorbitol pada saraf (p<0.05) dan buah pinggang (p<0.05), sebahagiannya melalui kawal selia aktiviti aldosa 
reduktase (p<0.05 untuk saraf) dan sorbitol dehydrogenase (p<0.05 untuk buah pinggang) jika dibandingkan dengan 
kumpulan yang tidak dirawat. Quercetin adalah perencat aldosa reduktase yang dikenal pasti dan boleh meningkatkan 
beberapa indeks metabolik yang berkaitan Diabetes Jenis 2. Dalam kajian ini, hasil kajian R. cinerea adalah setanding 
dengan atau lebih baik daripada quercetin, justeru menunjukkan bahawa ekstrak R. cinerea boleh menjadi calon yang 
berpotensi untuk menguruskan Diabetes Jenis 2 dan komplikasi yang berkaitan dengan pengumpulan sorbitol.
Kata kunci: Aldosa reduktase; Diabetes Jenis 2; Rhodamnia cinerea; sorbitol
INTRODUCTION
There is a growing burden of  Type 2 diabetes globally, 
which is driving the efforts for more effective ways 
to manage this disease. Moreover, currently available 
therapeutic options have so far fallen short of effectively 
managing the disease, due to side effects and narrow 
spectrum of activity that does not cover the multiple 
metabolic perturbations in this disease (Gurib-Fakim 2006; 
World Health Organization 2014). This has heightened 
interest in plant bioresources, which are seen as safer 
and more cost-effective options when compared with 
pharmaceutical agents. There is enough biodiversity in 
many countries to provide potential candidate plants with 
such medicinal potentials. Thus, there is an increasing drive 
to study plants that have hitherto been unexplored for their 
medicinal properties, which is what this study aimed to 
achieve. In particular, Malaysia is rich in biodiversity, and 
thus there has been an increasing drive to study plants with 
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potential anti-diabetic and other beneficial effects, some of 
which are already used as traditional medicine, in order to 
provide evidence-based justification for their usage (Adam 
et al. 2011; Nasir et al. 2015; Rahim et al. 2014).
 Rhodamnia cinerea, which belongs to the myrtle 
family, comprises of a group of rainforest trees and 
shrubs that are characterized by fleshy fruits (Govaerts et 
al. 2008). Their leaves are small and oblong, measuring 
around 2-7 cm. Not much is known regarding the medicinal 
properties of R. cinerea, although its leaves and roots are 
used for traditional medicine (Keng 1990; Scott 1979). 
Additionally, we recently observed for the first time that 
the aqueous extract of the plant had antidiabetic potentials 
using in vitro and in vivo testing, which has been filed for 
patent (Gehling et al. 2015). Thus, we hypothesized that 
the aqueous extract of R. Cinerea could improve metabolic 
indices, organ-specific sorbitol contents and organ-specific 
aldose reductase activities in Type 2 diabetic rats, which 
was tested in this study.
MATERIALS AND METHODS
MATERIALS 
Aldose reductase, F2-isoprostanes and Insulin ELISA kits 
were purchased from Elabscience Biotechnology Co. 
Ltd (Wuhan, China), while the deproteinization kit and 
total sorbitol content kit were purchased from Biovision 
(Mountain View, CA, USA) and Sigma Chemical Co. (St. 
Louis, Missouri, USA), respectively. RCL2® Solution 
was purchased from ALPHELYS (Toulouse, France). 
Kits for biochemical analyses were purchased from 
RandoxLaboratories Ltd (Crumlin, County Antrim, UK). 
The sugar and starch powders were purchased from R 
& S Marketing Sdn. Bhd. (Malaysia), while the Palm 
Oil, Nespray fortified milk powder and standard rat 
chow were purchased from Unilever (Malaysia), Nestle 
Manufacturing (Malaysia) and Specialty Feeds (TN, USA), 
respectively. Myricitrin reference standard (C21H20O12, 
CAS# 17912-87-7) was purchased from ChromaDex 
(CA, USA). Other chemicals and quercetin were purchased 
from Sigma-Aldrich Chemical (USA) and Thermo Fisher 
Scientific (Massachusetts, USA). 
PLANT MATERIAL 
R. cinerea was purchased from RD Agro Herbs, Serdang, 
Malaysia, and authenticated (voucher specimen PID 
170414-13) by Mr. Kamarudin Saleh from (Forest 
Research Institute Malaysia).
SOLVENT EXTRACTION 
The collected plant was washed several times with 
running tap water followed by deionized water and the 
aerial parts (leaves and stems) were dried for 4 days. The 
dried material was cut into smaller pieces and passed 
through a mesh opening of 6.0 mm sieve (Retsch SM 100, 
Germany). They were then mixed with water in the ratio 
of 1:10 and heated using hot plate for 3 h at 100oC. The 
mixtures were subsequently filtered through cotton wool 
(source and any spec) and the solvents were removed under 
reduced pressure (Rotavapor R210, Buchi, Switzerland) 
followed by spray drying (Buchi mini spray drier B-290, 
Switzerland). The dried crude extracts were stored at room 
temperature until further analysis.
HPLC ANALYSIS OF EXTRACT 
HPLC analysis was performed using Agilent 1200 series 
linked with diode array detector (Agilent, Stevens Creek 
Blvd Santa Clara, USA). Chromatographic separations were 
performed on a Phenomenex Kinetex, Analytical column 
(2.1 × 150 mm, 1.7μm). The mobile phase was composed 
of solvent (A) 0.1% formic acid in water and solvent 
(B) 0.1% formic acid in acetonitrile, with the respective 
solvent gradient: 95 and 5% (0 min), 95 and 5% (3 min), 
80 and 20% (8 min), 80 and 20% (16 min), 60 and 40% 
(22 min), 0 and 100% (25 min), 0 and 100% (30 min) and 
5 and 95% (33 min). A flow rate of 0.3 mL/ min was used 
and 2 µL of sample was injected. The samples and mobile 
phases were filtered through a 0.22 μm Millipore filter, 
type GV (Millipore, Bedford, MA) prior to HPLC injection. 
Each extract and fraction was analyzed in three replicates. 
Myricitrin was identified and quantified by comparing its 
retention times with authenticated standard (C21H20O12, 
CAS# 17912-87-7).
ANIMAL HANDLING 
Approval for use of animals was sought from the Animal 
Care and Use Committee (ACUC) of the Faculty of 
Medicine and Health Sciences, Universiti Putra Malaysia 
(Project approval number: UPM/IACUC/UAP-R045/2013) 
and the set guidelines for the use of animals were strictly 
adhered to. The animals (Sprague dawley rats, 10 weeks 
old, weighing 200-250 g, n=25) were obtained from 
Veterinary Medicine Faculty, Universiti Putra Malaysia 
and placed in plastic cages (two per cage). They were given 
free access to normal rat chow and water for 2 weeks to 
acclimatize under controlled conditions (25-30 °C , with 
a 12/12 h light/dark cycle). Thereafter, some rats (5 rats) 
were maintained on normal rat chow (normal group), 
while others were fed with high fat diet for 8 weeks and 
injected with streptozotocin (STZ) intraperitoneally (35 
mg/kg in sodium citrate buffer, pH 4.5) to induce Type 
2 diabetes (Imam & Maznah 2013). The normal group 
also received 5 mmol/L of sodium citrate buffer, pH 4.5 
intraperitoneally. The diabetic rats (fasting plasma glucose 
of ≥ 250 mg/dl after 2 days of STZ) were divided into 4 
groups (n=5); diabetic untreated, 100 mg/kg/day R. cinerea 
extract, 200 mg/kg/day R. cinerea extract and quercetin 
(10 mg/kg/day) groups. Food intake was maintained at 30 
kcal/100 g body weight/day for 4 weeks after injection of 
STZ. Weekly measurements of weight and fasting blood 
glucose were made using a laboratory measuring scale 
and glucometer, respectively. During sacrifice, fasting 
blood and tissue samples (liver, kidney, lens and sciatic 
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nerves) were collected for further tests. The tissues were 
immediately washed with ice-cold saline and stored in 
RCL2® Solution (ALPHELYS, France) at -80°C, while the 
blood was centrifuged at 3000 rpm for 10 min at 4°C to 
separate the serum. 
BIOCHEMICAL ANALYSES 
Kidney (urea and creatinine) and liver function (alanine 
transamine (ALT), aspartate transmaine (AST), alkaline 
phosphatase (ALP)) markers, and lipid profiles (total 
cholesterol (TC), low density lipoprotein (LDL), high density 
lipoprotein (HDL) and triglyceride (Trig)) were analyzed 
using Randox analytical kits according to manufacturer’s 
instructions on Selectra XL Clinical Chemistry Analyzer 
(Vita Scientific, Dieren, The Netherlands).
SERUM INSULIN AND F2-ISOPROSTANE AND LIVER 
ANTIOXIDANT STATUS 
Insulin and F2-isoprostane levels were measured from 
the serum samples collected, while liver samples were 
homogenized in cold phosphate buffered saline (1X PBS, pH 
7.4), centrifuged at 7000 rpm for 5 min and the supernatant 
used for total antioxidant status measurements using ELISA 
kits (Elabscience Biotechnology Co. Ltd, Wuhan, China) 
according to manufacturer’s instructions. Absorbances 
were read on BioTeK Synergy H1 Hybrid Reader (BioTek 
Instruments Inc., Winooski, VT, USA), and the results were 
analyzed on www.myassays.com (insulin, R² = 0.9954; 
F2-isoprostane, R² = 0.984; Antioxidant status, R² = 0.94).
KIDNEY, LENS AND SCIATIC NERVE ANTIOXIDANT STATUS, 
TOTAL SORBITOL AND ALDOSE REDUCTASE 
Tissues stored in RCL2 solution (kidney, lens and nerve) 
were homogenized in cold phosphate buffered saline (1X 
PBS, pH 7.4), centrifuged at 7000 rpm for 5 min and the 
supernatant used for total antioxidant status and aldose 
reductase activity. For sorbitol quantification, samples were 
deproteinized (Deproteinization kit, Biovision, Mountain 
View, CA, USA) prior to the assay. Tests were conducted 
using supernatants from the kidney, lens and nerves using 
the respective kits according to manufacturers’ instructions.
DATA ANALYSIS 
Data are presented as means ± SD (n=5). The normality 
of the distribution of the data was confirmed using the 
Shapiro-wilk normality test prior to one-way analysis 
of variance (ANOVA) on SPSS 17.0 software (SPSS Inc., 
Chicago, IL, USA). Differences between means were 
considered significant when p< 0.05.
RESULTS AND DISCUSSION
R. CINEREA ATTENUATED WEIGHT GAIN 
AND HYPERGLYCEMIA 
The use of plants for managing diseases has been practised 
for a long time, although in recent years there is renewed 
interest in plant bioreseources due to concerns of side 
effects and cost of pharmaceutical agents (Gurib-Fakim 
2006; Ismail & Imam 2014). In this study, we explored 
the potential antidiabetic effects of R. cinerea. The results 
showed that there was progressive decrease in glycemia 
in the R. cinerea-treated groups, although no significant 
difference was observed compared to the diabetic untreated 
group (Table 1). Improved glycemia suggested that the 
plant extract is able to regulate the sustained chronic 
hyperglycemia, which is the hallmark of Type 2 diabetes 
(Stumvoll et al. 2005), albeit not through improved insulin 
secretion (Table 2). Also, there was marked reduction in the 
weight of the diabetic untreated group (p<0.05) between 
the baseline 311 ± 20 g and week 4 (257 ± 38 g) (Table 
1), which can be attributed to gluconeogenesis. In Type 2 
diabetes, when body cells cannot take up glucose from the 
TABLE 1. Blood glucose and body weight changes over 4 weeks of intervention
Glucose (mmol/L)
Rat groups Baseline Week 1 Week 2 Week 3 Week 4
R. cinerea 100 mg
R. cinerea 200 mg
Quercetin
Diabetic untreated
Normal
18.7 ± 3.3 a
17.9 ± 3.6a
19.8 ± 4.1a
18.2 ± 0.8a
4.7 ± 0.5
14.6 ± 0.6 a
18.3 ± 2.0a
14.8 ± 3.4a
15.2 ± 1.8a
4.2 ± 0.2
16.5 ± 1.7a
16.8 ± 1.2 a
16.8 ± 1.2a
17.7 ± 2.3a
5.3 ± 1.3
16.7 ± 4.9 a
16.2 ± 1.6a
20.0 ± 4.3a
18.3 ± 1.6a
5.3 ± 0.9
15.1 ± 3.1 a
16.2 ± 1.6a
19.9 ± 4.2a
22.1 ± 4.8a
5.2 ± 0.8
Weight (g)
R. cinerea 100 mg
R. cinerea 200 mg
Quercetin
Diabetic untreated
Normal
290 ± 24
297 ± 37 
322 ± 57
311 ± 21
270 ± 21
261 ± 21
245 ± 43
302 ± 44
278 ± 29
288 ± 24
275 ± 13
249 ± 48
297 ± 53
261 ± 39
303 ± 25
272 ± 38
251 ± 49
303 ± 52
261 ± 38
316 ± 25
275 ± 43
244 ± 37a
296 ± 48
258 ± 38 a
325 ± 26
Data are mean ± SD (n=5). The normal group was fed normal pellet throughout the intervention, while the diabetic untreated group (high fat diet + 35 mg/
kg streptozotocin) received high fat diet for 4 weeks The quercetin, R. cinerea 100mg and R. cinerea 200 mg groups received qercetin (10 mg/kg/day) and 
100 mg/kg/day and 200 mg/kg/day of aqueous extract of R. cinerea in addition to the high fat diet for 4 weeks after diabetes induction. a indicates statistical 
difference in comparison with the normal group for either glucose or weight measurements in each column (p<0.05) 
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blood due to insulin insensitivity, endogenous production 
of glucose in the liver is increase from fats and proteins 
broken down from body stores (Magnusson et al. 1992). 
This may explain the marginal decrease in body weight 
in the quercetin group since quercetin has been shown to 
inhibit gluconeogenesis (Gasparin et al. 2003). Although 
there was weight reduction in the R. cinerea groups, it 
may have been due to weight-reducing properties of the 
extracts as suggested by the high dose use in this study, 
which was able to reduce the weights beyond that of the 
diabetic untreated group. 
R. CINEREA IMPROVED LIPID PROFILES, OXIDATIVE STRESS, 
AND LIVER AND KIDNEY FUNCTIONS 
Lipid profile, liver and kidney functions are dysregulated 
in Type 2 diabetes (Imam et al. 2013, 2012). In this study, 
R. cinerea significantly improved lipid profiles (Table 2) 
indicating that it may be able to prevent diabetes related 
cardiovascular diseases, which is an important cause of 
morbidity and mortality in Type 2 diabetes (Elkeles et al. 
1998). Moreover, the worsened liver and kidney function 
were improved by R. cinerea (Table 2) also suggesting 
the ability of the extract to improve overall metabolic 
condition and its lack of toxicity in diabetes. The 
attenuation of oxidative stress in the liver as evidenced 
by reduced F2-isoprostane (Roberts & Morrow 2000) in 
comparison with the untreated diabetic group (Table 2, 
p<0.05) further corroborates the improvement in overall 
metabolic condition of the diabetic rats as a result of 
feeding the R. cinerea extract. 
R. CINEREA ATTENUATED ALDOSE REDUCTASE 
ENZYME ACTIVITY
Sorbitol contents (Table 2) of the lens, nerve and kidney 
were elevated in the untreated group, while quercetin, 
which is known to lower sorbitol levels (Kador et al. 
1985), showed reduced levels in the lens and kidney 
(p<0.05). R. cinerea extract also reduced the sorbitol 
contents, especially of the kidney and nerve (p<0.05), 
which indicated that it may prevent sorbitol-related 
complications in type 2 diabetes including diabetic 
nephropathy and neuropathy. Because the activity of 
aldose reductase has been shown to influence sorbitol 
levels (Kador et al. 1985), we assayed the activities in 
the lens, kidney and nerve (Table 2). The results showed 
that the aldose reductase activities of the lens and nerve 
were significantly increased in the diabetic untreated 
group in comparison with the normal group, while the R. 
cinerea and quercetin groups attenuated these increases 
(p<0.05). The reduced aldose reductase activities in the 
lens and nerves of the R. cinerea groups likely contributed 
to the lower sorbitol contents in these tissues (Yabe-
Nishimura 1998), although other factors including the 
metabolic flux due to blood glucose may have played 
a role in the case of the kidney (Gabbay 1975), which 
showed lower sorbitol content but not aldose reductase 
activity. Similarly, the ability of the extract to regulate 
oxidative stress in these tissues may have played a role 
in the regulation of sorbitol. It has been demonstrated 
that increased oxidative stress propagates the buildup of 
sorbitol and other complications in Type 2 diabetes (Dey 
& Lakshmanan 2013; Rahimi et al. 2005) and the results 
from this study showed that the untreated diabetic control 
group had lower antioxidant capacities in the lens, kidney 
and nerve (Table 2), while the R. cinerea-treated groups 
had improved antioxidant capacities, although only those 
of the kidney were significant different (p<0.05). 
HPLC BIOACTIVE IDENTIFICATION 
The active compound identified in the aqueous extract of 
R. cinerea was myricetrin (1.013 ± 0.003% w/w extract), 
which is a flavonol rhamnoside of myricetin that is broken 
down to myricetin in the intestine (Smith & Griffiths 1970), 
although some of it is converted to a myricetrin glycoside 
prior to absorption (Matsukawa et al. 2012). Myricetrin has 
been shown to regulate intestinal glucose uptake (Postal 
et al. 2014) and weight gain (Maronpot et al. 2015), while 
its metabolite (myricetin) is widely acknowledged to 
have antidiabetic properties mediated via improvements 
in glycemia, weight and lipid profiles, antioxidation and 
aldose reductase inhibition (Li & Ding 2012; Ong & Khoo 
1997), similar to the effects observed in this study.
 In aggregate, our data showed that R. Cinerea could 
improve metabolic perturbations in Type 2 diabetic rats. 
Although some results were not significantly different 
between the R. cinerea-treated groups and the diabetic 
untreated group, perhaps longer treatment period could 
have produced more significant changes as indicted by 
the trend of improvements in the R. Cinerea groups. 
Therefore, R. cinerea can be a good candidate for diabetes 
management. Moreover, the inability of pharmaceutical 
agents to effectively prevent complications is the basis for 
the failure to effectively curb the burden of diabetes. These 
results suggested that the traditional use of R. cinerea for 
managing diseases may have been based on its ability to 
regulate multiple biochemical parameters as shown in the 
present study. Hence, R. cinerea has medicinal properties 
that can be developed into nutraceuticals for management 
of diabetes and its complications.
CONCLUSION
Type 2 diabetic rats treated with an aqueous extract of 
R. cinerea showed improved glycemia, lipid profiles and 
kidney and liver function markers. R. cinerea also regulated 
the activity aldose reductase and produced lower sorbitol 
contents of the nerve and kidney. Overall, the results of 
R. cinerea were comparable or even better than those of 
quercetin. Thus, R. cinerea extract can be a good candidate 
for the management of diabetic complications and other 
related metabolic disorders with lipid abnormalities and 
oxidative stress. However, there is need for long term 
studies to establish the translational implications of these 
findings.
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